Journal of Clinical Oncology
Articles in this Issue
Racial disparities in hepatocellular carcinoma admissions, comorbidities, and outcomes: A nationwide analysis from 2016-2021.
e16266 Background: Hepatocellular carcinoma (HCC) has had a rising incidence and mortality rate in recent years. Various risk factors have been identified...
A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
9514 Background: Given the success of checkpoint inhibitor therapy in the advanced setting in Merkel cell carcinoma (MCC),...
Targeting BCMA in relapsed and refractory multiple myeloma: A systematic review and meta-analysis of efficacy and safety of belantamab mafodotin.
e19512 Background: Relapsed or refractory multiple myeloma (RRMM) remains a significant therapeutic challenge, particularly for patients exposed to protea...
Global burden and trend of colorectal cancer and its attributable risk factors in Latin America and Caribbean from 1990-2021: A benchmarking secondary analysis.
e15686 Background: Colorectal Cancer (CRC) is the 2nd leading cause of death and 3rd leading cause of disability in Latin America (LA) and Caribbean. The...
Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.
2518 Background: Preclinical and clinical evidence has suggested the role of natural killer (NK) cells in tumor immunity and prognosis across various canc...
Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
5556 Background: While poly(ADP-ribose) polymerase inhibitors (PARPi) have demonstrated clinical success in prolonging progression-free survival (PFS) in...
Establishment and validation of a dynamic prognostic model using serial circulating tumor DNA (ctDNA) for endemic EBV-related nasopharyngeal carcinoma (NPC): A secondary analysis of EP-SEASON.
6049 Background: Published risk prediction tools have focused on pretreatment factors, whereas the accuracy remains challenging in cancer care. Emerging e...
Advancing AI in oncology: A performance comparison of ChatGPT-4o and ChatGPT-o1 in neuroendocrine tumor clinical decision making.
e13730 Background: Artificial intelligence (AI) is increasingly integrated into clinical decision-making, offering potential support in complex oncologic...
Real-world outcomes of inaticabtagene autoleucel in Chinese patients with B-ALL.
6529 Background: Inaticabtagene autoleucel (Inati-cel) is a CD19-specific chimeric antigen receptor (CAR) T-cell product, featuring a CD19 scFv derived fr...
A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).
TPS4229 Background: Pancreatic cancer is a highly lethal disease. Despite research and drug development efforts focused on KRAS, no effective RAS inhibito...
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.
7516 Background: After readout of the PERSEUS and CEPHEUS trials, daratumumab-based therapy + VRd is emerging as the standard of care in NDMM treatment. I...
Association of food insecurity and financial hardship with healthcare utilization among adults with cancer treated in a large, urban cancer center.
e13579 Background: Patients with cancer are particularly vulnerable to financial toxicity (FT), which can impact their access to food and other basic reso...
A phase IIa clinical trial of ABP1011T monotherapy in patients with advanced malignant solid tumors.
e15145 Background: ABP1011 T is an innovative tyrosine kinase inhibitor (TKI) that effectively inhibits EGFR, c-MET, FGFR1-4, VEGFR1-3, RET, and c-KIT. Im...
A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.
e16442 Background: Nab-paclitaxel combined with gemcitabine (AG) is the standard neoadjuvant treatment regimen for pancreatic cancer (PC). Research shows...
Age-stratified analysis of socioeconomic disparities in non-small cell lung cancer outcomes: A National Cancer Database study.
e13780 Background: Despite proven screening strategies and treatment advances, non-small cell lung cancer (NSCLC) remains the most lethal cancer worldwide...
Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.
508 Background: Vasomotor symptoms (VMS) associated with adjuvant endocrine therapy (AET) impact quality of life and decrease treatment adherence, worseni...
Disparities in NIH and federal cancer research funding across different cancer types.
11025 Background: National Institutes of Health (NIH) and other federal funding resources are critical for research and advocacy, but may not be equitably...
LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.
TPS1124 Background: Endocrine-based therapy (ET), with or without cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), prolongs PFS and OS in participants (p...
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.
4130 Background: Growing evidence supports the prognostic and predictive value of circulating tumor DNA (ctDNA) detection in gastrointestinal cancers. Bui...
Evaluating barriers to timely NSCLC treatment: A northern Nevada perspective.
e23074 Background: Renown Regional Medical Center (RRMC) in Reno, Nevada, serves as a primary treatment center for non-small cell lung cancer (NSCLC) pati...
Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials.
e20551 Background: Lung cancer is leading cause of cancer related mortality globally, with non-small cell lung cancer (NSCLC) comprising approximately 80%...
Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
6065 Background: C-POST is a phase 3, double-blind, pbo-controlled trial (NCT03969004) of adjuvant cemi for treatment of patients (pts) with CSCC at high...
Virtual personalized exercise program for subjects with lung cancer: A feasibility study.
TPS12144 Background: With improved outcomes, cancer is increasingly viewed as a chronic disease, highlighting the need for exercise programs to enhance th...
Dynamic prediction of cancer-associated thrombosis to guide prophylactic anticoagulation.
e13696 Background: Cancer-associated thrombosis (CAT) is preventable among high-risk individuals through prophylactic anticoagulation. Current guidelines...
Socioeconomic disparities in pancreatic cancer treatment: The role of pre-diagnosis healthcare utilization.
e16384 Background: Pancreatic cancer treatment patterns vary widely, influenced by a range of factors beyond clinical characteristics. Access to timely an...